Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 10/20 | 0.41 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29680582 | 1.00 | RORC (0.41) | RORCSMYD2SCD5GAATHRB | |
| SCHEMBL29080094 | 0.90 | SMYD2 (0.39) | SMYD2SMN1; SMN2 | |
| SCHEMBL553857 | 0.84 | EPHA2 (0.45) | GAATHRBSMN1; SMN2GPR119EPHA2 | |
| SCHEMBL553856 | 0.84 | EPHA2 (0.45) | GAATHRBSMN1; SMN2GPR119EPHA2 | |
| SCHEMBL30987202 | 0.84 | NR1H2 (0.34) | RORCTHRBSMN1; SMN2EPHA2KDM4E | |
| SCHEMBL30987065 | 0.84 | NR1H2 (0.34) | RORCTHRBSMN1; SMN2EPHA2KDM4E | |
| SCHEMBL30987095 | 0.82 | RORC (0.42) | RORCGAATHRBSMN1; SMN2GPR119 | |
| SCHEMBL31299244 | 0.82 | NAMPT (0.37) | RORCSMYD2GAATHRBSMN1; SMN2 | |
| SCHEMBL29680617 | 0.82 | NAMPT (0.37) | RORCSMYD2GAATHRBSMN1; SMN2 | |
| SCHEMBL31299259 | 0.81 | NAMPT (0.37) | RORCSMYD2GAATHRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624033-B2 | KRAS inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735439-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735440-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250250271-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250154148-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-05-15 | — | — | US | disclosed |
| WO-2025006962-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025006967-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154148-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | RORC 2272/4885SMYD2 1603/4885SCD5 4238/4885 |
| US-20250250271-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | RORC 2272/4885SMYD2 1603/4885SCD5 4238/4885 |
| US-12624033-B2 | KRAS inhibitors | KRAS, NRAS, BRAF | RORC 3778/4885SMYD2 2034/4885SCD5 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.